No significant weaknesses identified
| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ADMAADMA Biologics, Inc. | 4.35B | 18.28 | 22.57 | 65.15% | 42.87% | 48.57% | 2.53% | 0.24 |
| CVACCureVac N.V. | 1.05B | 4.66 | 6.47 | 8.96% | 37.93% | 33.02% | 7.95% | 0.06 |
| DWTXDogwood Therapeutics, Inc. | 86.21M | 2.90 | -0.23 | -49.37% | 0.24 | |||
| INOInovio Pharmaceuticals, Inc. | 112.67M | 1.64 | -0.42 | -73.83% | -592.82% | -115.42% | 0.17 | |
| ALGSAligos Therapeutics, Inc. | 48.45M | 9.05 | -0.43 | -74.6% | -32.68% | -120.37% | ||
| BRNSBarinthus Biotherapeutics plc | 30.83M | 0.76 | -0.49 | 17.66% | -408% | -89.73% | 0.09 | |
| COCPCocrystal Pharma, Inc. | 15.99M | 1.16 | -0.67 | -126.11% | 0.19 | |||
| KLRSKalaris Therapeutics Inc | 172.81M | 9.24 | -0.79 | -170.84% |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 12.87M | 17.42M | 48.9M | 102.99M | 67.42M | 53.76M | 535.18M |
| Revenue Growth % | - | 0.35% | 1.81% | 1.11% | -0.35% | -0.2% | 8.96% |
| Cost of Goods Sold | 17.74M | 27.98M | 14.17M | 238.19M | 183.99M | 124.37M | 105.83M |
| COGS % of Revenue | 1.38% | 1.61% | 0.29% | 2.31% | 2.73% | 2.31% | 0.2% |
| Gross Profit | -4.87M | -10.57M | 34.73M | -135.21M | -116.57M | -70.61M | 429.35M |
| Gross Margin % | -0.38% | -0.61% | 0.71% | -1.31% | -1.73% | -1.31% | 0.8% |
| Gross Profit Growth % | - | -1.17% | 4.29% | -4.89% | 0.14% | 0.39% | 7.08% |
| Operating Expenses | 67.95M | 88.93M | 158.7M | 277.06M | 134.28M | 203.6M | 251.67M |
| OpEx % of Revenue | 5.28% | 5.11% | 3.25% | 2.69% | 1.99% | 3.79% | 0.47% |
| Selling, General & Admin | 21.5M | 43.94M | 45.76M | 88.94M | 89.41M | 76.43M | 74.33M |
| SG&A % of Revenue | 1.67% | 2.52% | 0.94% | 0.86% | 1.33% | 1.42% | 0.14% |
| Research & Development | 41.72M | 43.24M | 113.81M | 815.91M | 62.55M | 115.72M | 153.03M |
| R&D % of Revenue | 3.24% | 2.48% | 2.33% | 7.92% | 0.93% | 2.15% | 0.29% |
| Other Operating Expenses | 4.73M | 1.75M | -870K | -627.79M | -17.68M | 11.44M | 24.3M |
| Operating Income | -72.82M | -99.5M | -124M | -412.26M | -249.46M | -274.21M | 177.68M |
| Operating Margin % | -5.66% | -5.71% | -2.54% | -4% | -3.7% | -5.1% | 0.33% |
| Operating Income Growth % | - | -0.37% | -0.25% | -2.32% | 0.39% | -0.1% | 1.65% |
| EBITDA | -68.94M | -94.74M | -110.39M | -376.38M | -223.3M | -250.82M | 196.49M |
| EBITDA Margin % | -5.36% | -5.44% | -2.26% | -3.65% | -3.31% | -4.67% | 0.37% |
| EBITDA Growth % | - | -0.37% | -0.17% | -2.41% | 0.41% | -0.12% | 1.78% |
| D&A (Non-Cash Add-back) | 3.89M | 4.76M | 13.61M | 35.88M | 26.16M | 23.39M | 18.81M |
| EBIT | -70.86M | -98.67M | -107.75M | -402.16M | -245.45M | -257.48M | 190.88M |
| Net Interest Income | 1.69M | -627K | -20.03M | -235K | 302K | 14.24M | 12.36M |
| Interest Income | 1.97M | 833K | 2.07M | 10.1M | 4.01M | 16.73M | 12.36M |
| Interest Expense | 275K | 1.46M | 22.1M | 10.34M | 3.71M | 2.49M | 0 |
| Other Income/Expense | 1.69M | -627K | -20.03M | -235K | 302K | 14.24M | 13.2M |
| Pretax Income | -71.13M | -100.13M | -129.8M | -412.5M | -249.16M | -259.97M | 190.88M |
| Pretax Margin % | -5.53% | -5.75% | -2.65% | -4.01% | -3.7% | -4.84% | 0.36% |
| Income Tax | 110K | -252K | -726K | -782K | -126K | 198K | 28.7M |
| Effective Tax Rate % | 1% | 1% | 0.99% | 1% | 1% | 1% | 0.85% |
| Net Income | -71.24M | -99.87M | -129.07M | -411.72M | -249.03M | -260.17M | 162.19M |
| Net Margin % | -5.54% | -5.73% | -2.64% | -4% | -3.69% | -4.84% | 0.3% |
| Net Income Growth % | - | -0.4% | -0.29% | -2.19% | 0.4% | -0.04% | 1.62% |
| Net Income (Continuing) | -71.24M | -99.87M | -129.12M | -411.72M | -249.03M | -260.17M | 162.19M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.40 | -0.53 | -0.98 | -2.21 | -1.32 | -1.18 | 0.72 |
| EPS Growth % | - | -0.33% | -0.85% | -1.26% | 0.4% | 0.11% | 1.61% |
| EPS (Basic) | -0.40 | -0.53 | -0.98 | -2.21 | -1.32 | -1.18 | 0.72 |
| Diluted Shares Outstanding | 175.97M | 186.91M | 132.2M | 186.01M | 189.07M | 220.83M | 225.27M |
| Basic Shares Outstanding | 175.97M | 186.91M | 132.2M | 186.01M | 189.07M | 220.48M | 224.38M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 73.07M | 57.17M | 1.39B | 940.02M | 584.03M | 478.38M | 526.41M |
| Cash & Short-Term Investments | 60.63M | 32.14M | 1.33B | 816.11M | 500.28M | 405.11M | 485.37M |
| Cash Only | 21.38M | 30.68M | 1.32B | 811.46M | 495.8M | 402.45M | 481.75M |
| Short-Term Investments | 39.25M | 1.46M | 2.62M | 4.65M | 4.49M | 2.66M | 3.62M |
| Accounts Receivable | 6.86M | 17.15M | 1.82M | 53.74M | 9M | 39.51M | 32.9M |
| Days Sales Outstanding | 194.48 | 359.49 | 13.6 | 190.45 | 48.74 | 268.26 | 22.44 |
| Inventory | 2.95M | 6.2M | 14.53M | 56.16M | 23.99M | 24.8M | 541K |
| Days Inventory Outstanding | 60.7 | 80.83 | 374.22 | 86.06 | 47.59 | 72.79 | 1.87 |
| Other Current Assets | 0 | 0 | 0 | 8.29M | 15.81M | 7.88M | 6.81M |
| Total Non-Current Assets | 52.59M | 73.44M | 121.5M | 218.22M | 276.44M | 309.87M | 276.41M |
| Property, Plant & Equipment | 45.49M | 66.78M | 104.79M | 200.39M | 241.7M | 278.63M | 244.65M |
| Fixed Asset Turnover | 0.28x | 0.26x | 0.47x | 0.51x | 0.28x | 0.19x | 2.19x |
| Goodwill | 0 | 0 | 0 | 0 | 12.46M | 12.46M | 12.46M |
| Intangible Assets | 6.21M | 5.7M | 14.15M | 13.24M | 19.32M | 15.88M | 12.69M |
| Long-Term Investments | 749K | 0 | 1.03M | 515K | 0 | -4K | 0 |
| Other Non-Current Assets | 1K | 967K | 1.09M | 1.22M | 1.67M | 1.7M | 1.51M |
| Total Assets | 125.66M | 130.62M | 1.51B | 1.16B | 860.47M | 788.25M | 802.83M |
| Asset Turnover | 0.10x | 0.13x | 0.03x | 0.09x | 0.08x | 0.07x | 0.67x |
| Asset Growth % | - | 0.04% | 10.57% | -0.23% | -0.26% | -0.08% | 0.02% |
| Total Current Liabilities | 28.13M | 28.09M | 247.62M | 357.73M | 156.22M | 186.39M | 72.35M |
| Accounts Payable | 9.03M | 5.33M | 17.62M | 122.26M | 68.25M | 48.03M | 17.27M |
| Days Payables Outstanding | 185.73 | 69.54 | 453.85 | 187.35 | 135.38 | 140.97 | 59.57 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 0 |
| Other Current Liabilities | 11.92M | 11.84M | 55.58M | 171.38M | 44.69M | 88.74M | 31.5M |
| Current Ratio | 2.60x | 2.04x | 5.61x | 2.63x | 3.74x | 2.57x | 7.28x |
| Quick Ratio | 2.49x | 1.82x | 5.55x | 2.47x | 3.58x | 2.43x | 7.27x |
| Cash Conversion Cycle | 69.45 | 370.78 | -66.03 | 89.15 | -39.06 | 200.08 | -35.26 |
| Total Non-Current Liabilities | 65.45M | 145.34M | 552.39M | 112.03M | 170.99M | 84.92M | 33.87M |
| Long-Term Debt | 0 | 65.02M | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 12.13M | 26.85M | 25.42M | 37.11M | 36.82M | 33.64M |
| Deferred Tax Liabilities | 0 | 1.62M | 0 | 0 | 0 | 0 | 227K |
| Other Non-Current Liabilities | 863K | 68.19M | 25.47M | 86.61M | 133.89M | 0 | 0 |
| Total Liabilities | 93.58M | 173.42M | 800.01M | 469.77M | 327.22M | 271.31M | 106.22M |
| Total Debt | 77K | 79.15M | 30.09M | 28.89M | 42.09M | 41.82M | 38.97M |
| Net Debt | -21.3M | 48.46M | -1.29B | -782.57M | -453.71M | -360.63M | -442.78M |
| Debt / Equity | 0.00x | - | 0.04x | 0.04x | 0.08x | 0.08x | 0.06x |
| Debt / EBITDA | - | - | - | - | - | - | 0.20x |
| Net Debt / EBITDA | - | - | - | - | - | - | -2.25x |
| Interest Coverage | -264.81x | -68.15x | -5.61x | -39.88x | -67.29x | -109.99x | - |
| Total Equity | 32.08M | -42.8M | 711.35M | 688.48M | 533.25M | 516.94M | 696.61M |
| Equity Growth % | - | -2.33% | 17.62% | -0.03% | -0.23% | -0.03% | 0.35% |
| Book Value per Share | 0.18 | -0.23 | 5.38 | 3.70 | 2.82 | 2.34 | 3.09 |
| Total Shareholders' Equity | 32.08M | -42.8M | 711.35M | 688.48M | 533.25M | 516.94M | 696.61M |
| Common Stock | 727K | 727K | 21.66M | 22.45M | 23.4M | 26.88M | 26.92M |
| Retained Earnings | -416.07M | -515.95M | -645.07M | -1.06B | -1.31B | -1.57B | -1.4B |
| Treasury Stock | 0 | 0 | 0 | -5.82M | -1.48M | 0 | 0 |
| Accumulated OCI | 447.43M | 472.42M | 1.33B | 1.73B | 1.82B | 2.06B | 2.07B |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -74.11M | -86.96M | 522.4M | -733.13M | -286.18M | -267.89M | 101.85M |
| Operating CF Margin % | -5.76% | -4.99% | 10.68% | -7.12% | -4.24% | -4.98% | 0.19% |
| Operating CF Growth % | - | -0.17% | 7.01% | -2.4% | 0.61% | 0.06% | 1.38% |
| Net Income | -71.13M | -100.13M | -129.85M | -412.5M | -249.16M | -260.17M | 190.88M |
| Depreciation & Amortization | 3.78M | 7.16M | 10.67M | 15.67M | 23.74M | 23.39M | 18.81M |
| Stock-Based Compensation | -4.25M | 19.56M | 14.24M | 14.96M | 9.19M | 7.7M | 4.12M |
| Deferred Taxes | 52K | -847K | -2.87M | 199.02M | -1.58M | 0 | 0 |
| Other Non-Cash Items | -1.48M | 9.93M | 51.63M | -480.74M | 57.2M | 29.49M | 52M |
| Working Capital Changes | -1.08M | -22.65M | 578.57M | -69.55M | -125.56M | -68.29M | -163.96M |
| Change in Receivables | -5.59M | -10.12M | -32.3M | -19.82M | -16.68M | -7.92M | 11.47M |
| Change in Inventory | 878K | -3.25M | -8.33M | -227.46M | -47.85M | -46.96M | 590K |
| Change in Payables | 9.4M | -9.58M | 620.3M | 179.32M | -96.19M | -29.37M | -140.58M |
| Cash from Investing | -4.26M | 28.18M | -45.27M | -127.9M | -93.5M | -55.2M | -18.44M |
| Capital Expenditures | -14.72M | -12.22M | -47.35M | -127.9M | -93.22M | -52.32M | -14.31M |
| CapEx % of Revenue | 1.14% | 0.7% | 0.97% | 1.24% | 1.38% | 0.97% | 0.03% |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 5.14M | 2.33M | 3.24M | -3.68M | -5.2M | -2.88M | -4.13M |
| Cash from Financing | -112K | 67.98M | 819.83M | 344.96M | 63.17M | 230.89M | -5.11M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 0 | 0 | 0 | 0 | 0 | 246K | 0 |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -88.83M | -99.19M | 475.05M | -861.03M | -379.4M | -323.09M | 83.41M |
| FCF Margin % | -6.9% | -5.7% | 9.71% | -8.36% | -5.63% | -6.01% | 0.16% |
| FCF Growth % | - | -0.12% | 5.79% | -2.81% | 0.56% | 0.15% | 1.26% |
| FCF per Share | -0.50 | -0.53 | 3.59 | -4.63 | -2.01 | -1.46 | 0.37 |
| FCF Conversion (FCF/Net Income) | 1.04x | 0.87x | -4.05x | 1.78x | 1.15x | 1.03x | 0.63x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -222.05% | - | -38.61% | -58.82% | -40.77% | -49.55% | 26.73% |
| Return on Invested Capital (ROIC) | -506.66% | -907.72% | - | - | -235.21% | -174.39% | 64.98% |
| Gross Margin | -37.86% | -60.67% | 71.02% | -131.28% | -172.91% | -131.34% | 80.23% |
| Net Margin | -553.5% | -573.46% | -263.95% | -399.76% | -369.37% | -483.96% | 30.3% |
| Debt / Equity | 0.00x | - | 0.04x | 0.04x | 0.08x | 0.08x | 0.06x |
| Interest Coverage | -264.81x | -68.15x | -5.61x | -39.88x | -67.29x | -109.99x | - |
| FCF Conversion | 1.04x | 0.87x | -4.05x | 1.78x | 1.15x | 1.03x | 0.63x |
| Revenue Growth | - | 35.31% | 180.78% | 110.61% | -34.54% | -20.26% | 895.54% |
| 2022 | 2023 | |
|---|---|---|
| Product | - | 11.39M |
| Product Growth | - | - |
| Research and development services | 19.57M | 11.31M |
| Research and development services Growth | - | -42.20% |
CureVac N.V. (CVAC) has a price-to-earnings (P/E) ratio of 6.5x. This may indicate the stock is undervalued or faces growth challenges.
CureVac N.V. (CVAC) reported $510.5M in revenue for fiscal year 2024. This represents a 3866% increase from $12.9M in 2018.
CureVac N.V. (CVAC) grew revenue by 895.5% over the past year. This is strong growth.
Yes, CureVac N.V. (CVAC) is profitable, generating $193.6M in net income for fiscal year 2024 (30.3% net margin).
CureVac N.V. (CVAC) has a return on equity (ROE) of 26.7%. This is excellent, indicating efficient use of shareholder capital.
CureVac N.V. (CVAC) generated $196.1M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.